Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement
Rhea-AI Summary
Tevogen (Nasdaq: TVGN) announced it has regained compliance with the Nasdaq minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) as of March 25, 2026. The Bid Price Requirement is a $1.00 per share closing threshold.
Tevogen previously received a notice on September 23, 2025 for failing to meet the $1.00 closing bid for 30 consecutive business days. With compliance restored, the company says it will continue pursuing a diversified healthcare strategy combining immunotherapy, artificial intelligence, and disciplined capital allocation, and will evaluate targeted acquisition opportunities while working toward a cash-flow-positive operating model.
Positive
- Regained compliance with Nasdaq Listing Rule 5450(a)(1) as of March 25, 2026
- Meets the $1.00 minimum bid price requirement required for continued Nasdaq Global Market listing
Negative
- Previously below the $1.00 minimum bid price for 30 consecutive business days (notice dated September 23, 2025)
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed warrant moves: CELUW up 2.5%, while NLSPW and BCTXW declined 12.25% and 50%, respectively. With TVGNW down 3.35% and no peers in the momentum scanner, trading appears stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | Conference participation | Positive | +1.9% | CIO speaking at Microsoft Fabric Community Conference on Tevogen.AI themes. |
| Mar 13 | Capital discipline update | Positive | +0.6% | Reaffirmed limited share use, concentrated float, and potential revenue-adding deals. |
| Mar 13 | AI platform progress | Positive | +0.6% | Reported improved PredicTcell™ metrics and expanded proprietary AI data assets. |
| Mar 11 | Long COVID program | Positive | +0.3% | Advanced TVGN 489 toward next clinical phase with supportive proof-of-concept data. |
| Mar 09 | Leadership & M&A plan | Positive | +0.0% | Named interim leaders and outlined acquisitions targeting >$50M annual revenue. |
Recent news—including AI, capital discipline, and pipeline updates—has generally seen modestly positive price reactions, suggesting incremental alignment between announcements and short-term trading.
Over the past few weeks, Tevogen has highlighted multiple strategic pillars. On Mar 9 2026, it named a leadership team and outlined potential acquisitions targeting annual revenues above $50 million. Subsequent updates covered Long COVID progress for TVGN 489, AI platform advances using 655 million peptide sequences, and capital-discipline messaging tied to limited share utilization and a tradable float near 20%. The current compliance update fits this broader effort to stabilize its listing while executing a diversified growth strategy.
Regulatory & Risk Context
The company has an active S-3 shelf registration filed on 2025-06-20, effective through 2028-06-20, with at least 4 recorded usage events via prospectus supplements. This framework provides flexibility to access capital when needed.
Market Pulse Summary
This announcement confirms Tevogen has regained compliance with Nasdaq’s $1.00 minimum bid-price requirement, reducing immediate listing risk. It fits alongside recent disclosures on diversified growth plans, potential acquisitions targeting over $50 million in revenue, and AI platform development using 655 million peptide sequences. Investors may monitor future capital-raising activity under the effective S-3 and progress toward the stated goal of a cash-flow-positive operating model.
Key Terms
nasdaq listing rule 5450(a)(1) regulatory
minimum bid price requirement regulatory
the nasdaq global market regulatory
AI-generated analysis. Not financial advice.
WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC notifying the Company that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market.
As previously disclosed on September 23, 2025, the Company received a notification letter from the Staff of Nasdaq indicating that the Company was not in compliance with the minimum bid price requirement of
With compliance restored, Tevogen continues to advance its evolution into a diversified, fully integrated healthcare enterprise, combining immunotherapy, artificial intelligence, and disciplined capital allocation to drive long-term value.
The Company’s strategic direction includes evaluating targeted acquisition opportunities that complement its core platforms. These initiatives are part of a broader effort to transition toward a cash-flow-positive operating model while maintaining a strong commitment to affordability and efficiency.
About Tevogen
Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.
Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio’s pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.
Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.
Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: the potential transactions and the potential benefits of the transactions; Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: risks inherent in diligence and negotiation of the proposed transactions; the risk that the transactions may not be consummated on favorable terms or at all; the risk that the expected benefits of the transactions may not be realized on a timely basis or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s most recent Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contact
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f60a78cf-4174-49e3-9b69-91112634877d
FAQ
What does Tevogen's March 25, 2026 Nasdaq compliance notice mean for TVGN shareholders?
How did Tevogen become noncompliant with Nasdaq before regaining compliance on March 25, 2026?
Will Tevogen (TVGN) remain listed on the Nasdaq Global Market after regaining compliance?
Does Tevogen plan any strategic changes after regaining Nasdaq compliance (TVGN)?
What was the specific Nasdaq bid price requirement referenced in Tevogen's March 25, 2026 announcement?
